Home » Stocks » PODD

Insulet Corporation (PODD)

Stock Price: $281.20 USD 0.00 (0.00%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 18.54B
Revenue (ttm) 867.69M
Net Income (ttm) 28.87M
Shares Out 65.72M
EPS (ttm) 0.44
PE Ratio 639.09
Forward PE 243.90
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $281.20
Previous Close $281.20
Change ($) 0.00
Change (%) 0.00%
Day's Open 285.28
Day's Range 274.11 - 288.53
Day's Volume 768,195
52-Week Range 130.01 - 288.53

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 19 hours ago

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (O...

Business Wire - 1 week ago

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced ...

Investopedia - 3 weeks ago

These are the stocks with the best value, fastest growth, and most momentum for January.

Other stocks mentioned: AGCO, BDN, BPYU, ENPH, FSLY, HDS, MRNA, NLOK, NRG, ROK, TSLA, UNM, ZM
Investopedia - 3 weeks ago

These are the healthcare stocks with the best value, fastest growth, and most momentum for January 2021.

Other stocks mentioned: BIIB, BIO, CVS, HZNP, MRNA, QDEL, XLRN, XLV
Business Wire - 4 weeks ago

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced ...

Zacks Investment Research - 1 month ago

Insulet (PODD) reported earnings 30 days ago. What's next for the stock?

Investopedia - 1 month ago

These are the healthcare stocks with the best value, fastest growth, and most momentum for December 2020.

Other stocks mentioned: BIO, XLV, MRNA
Investors Business Daily - 2 months ago

Medical stocks could be making a comeback this year. The best-performing among them include medical technology companies with high Composite Ratings, a key metric measuring growth.

Other stocks mentioned: ALGN, QDEL, RGEN, RMD
Business Wire - 2 months ago

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced ...

Zacks Investment Research - 2 months ago

Insulet's (PODD) Q3 gross margin improvement can be primarily attributed to performance of the company's U.S. manufacturing and favorable revenue mix from the shift to higher volume

Seeking Alpha - 2 months ago

Insulet's (PODD) CEO Shacey Petrovic on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Insulet (PODD) delivered earnings and revenue surprises of 183.33% and 5.81%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 2 months ago

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (O...

Business Wire - 2 months ago

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (O...

Business Wire - 2 months ago

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (O...

Zacks Investment Research - 2 months ago

Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insider Monkey - 2 months ago

Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking ...

Business Wire - 2 months ago

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (O...

Zacks Investment Research - 3 months ago

This year, the technology sector is leading the V-shaped recovery from the unprecedented health-hazard-led economic devastation.

Other stocks mentioned: CPRT, ENTG, INTU, ZM
Business Wire - 3 months ago

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, t...

Zacks Investment Research - 3 months ago

Insulet (PODD) is optimistic about maintaining growth momentum of its Omnipod system along with tapping the booming diabetes market.

Investopedia - 3 months ago

These are the healthcare stocks with the best value, fastest growth, and most momentum for October 2020.

Other stocks mentioned: BIIB, BIO, CVS, IMMU, LVGO, MRNA, PRGO, QDEL
Zacks Investment Research - 3 months ago

Here are a few diabetes-centric MedTech stocks that investors can focus on to reap profits amid the pandemic-battered stock market situation.

Other stocks mentioned: ABT, DXCM, MDT
Zacks Investment Research - 3 months ago

Insulet (PODD) adds significant capacity in preparation of the Omnipod 5 launch in 2021.

Business Wire - 3 months ago

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (O...

Zacks Investment Research - 4 months ago

Insulet (PODD) reported earnings 30 days ago. What's next for the stock?

Investors Business Daily - 4 months ago

A Relative Strength Rating upgrade for Insulet shows improving technical performance. The post Insulet Shows Market Leadership With Jump To 82 RS Rating appeared first on Investor's Business D...

Forbes - 4 months ago

The Dow Jones is looking to finish with 2020 gains at this point, the last of the major 3 indexes to reclaim the title. For those thinking that valuations have run too hot.

Other stocks mentioned: CHWY, FUN, NAV, NYMT
Zacks Investment Research - 4 months ago

Insulet (PODD) adds significant capacity in preparation for the Omnipod 5 launch in 2021.

Zacks Investment Research - 5 months ago

Insulet's (PODD) total Omnipod product line comes up with record revenue growth.

Seeking Alpha - 5 months ago

Insulet's (PODD) CEO Shacey Petrovic on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Insulet (PODD) delivered earnings and revenue surprises of 2300.00% and 6.79%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 5 months ago

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (O...

Zacks Investment Research - 5 months ago

Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investors Business Daily - 5 months ago

Insulet sees its Relative Strength Rating hit the 80-plus level. The post Insulet Shows Market Leadership With Jump To 81 RS Rating appeared first on Investor's Business Daily.

Seeking Alpha - 6 months ago

Insulet: A Good Time To Pick Up A Promising Stock

Business Wire - 6 months ago

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System),...

The Motley Fool - 6 months ago

As the prevalence of diabetes has grown, these companies are looking for solutions.

Other stocks mentioned: DXCM, LVGO
The Motley Fool - 7 months ago

Here’s why a company making an essential and widely popular insulin pump is a solid buy amidst the backdrop of the COVID-19 pandemic.

The Motley Fool - 7 months ago

The COVID-19 pandemic is presenting a headwind, but Insulet's recurring-revenue-generating business model helps insulate it.

The Motley Fool - 7 months ago

These four companies have tremendous growth potential going into 2020.

Other stocks mentioned: EDIT, PAAS, TRUP
Zacks Investment Research - 8 months ago

Insulet's (PODD) first-quarter 2020 results reflect mixed segmental performance amid the coronavirus-led economic crisis.

Seeking Alpha - 8 months ago

Insulet Corporation (PODD) CEO Shacey Petrovic on Q1 2020 Results - Earnings Call Transcript

Investors Business Daily - 8 months ago

Stock Market Uptrend Strengthens Despite Weak Jobs Report

The Nasdaq gapped above the 9,000 level and soared nearly 6% for the week, helped by several strong earnings reports.aax

Other stocks mentioned: AAXN, CMG
Zacks Investment Research - 8 months ago

Insulet (PODD) delivered earnings and revenue surprises of -50.00% and 4.81%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Investors Business Daily - 8 months ago

Insulet reported a net loss of 3 cents per share on $198 million in sales. Losses were deeper than expected, but sales beat.

Zacks Investment Research - 8 months ago

Medical Product companies have partially mitigated the impact of the pandemic with the massive adoption of COVID-19 related healthcare-support products and services.

Other stocks mentioned: ABC, BDX, PEN
Investors Business Daily - 8 months ago

Nasdaq Moves Up: Shopify, PayPal, Insulet Near Buys With Earnings Due

Shopify, PayPal and Insulet are near buy points with earnings due this week.

Other stocks mentioned: PYPL, SHOP
The Motley Fool - 8 months ago

Shares of the tubeless insulin pump maker are also outperforming the market in 2020.

Investors Business Daily - 8 months ago

You can't follow all of this week's reports, but keep an eye on Shopify, PayPal, Apple supplier Lumentum and others near buy points with earnings due.

Other stocks mentioned: AAPL, LITE, MTCH, PYPL, SHOP

About PODD

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Its Omnipod System comprise two devices: a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, and its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in... [Read more...]

Industry
Medical Devices
IPO Date
May 15, 2007
CEO
Shacey Petrovic
Employees
1,350
Stock Exchange
NASDAQ
Ticker Symbol
PODD
Full Company Profile

Financial Performance

In 2019, Insulet's revenue was $738.20 million, an increase of 30.93% compared to the previous year's $563.80 million. Earnings were $11.60 million, an increase of 251.52%.

Financial Statements

Analyst Forecasts

According to 21 analysts, the average rating for Insulet stock is "Buy." The 12-month stock price forecast is 261.88, which is a decrease of -6.87% from the latest price.

Price Target
$261.88
(-6.87% downside)
Analyst Consensus: Buy